Cadence Pharmaceuticals Appoints Laureen DeBuono to its Board of Directors
SAN DIEGO, Aug. 15, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today the appointment of Laureen DeBuono to the company's board of directors. Ms. DeBuono will also serve as a member of the company's audit committee.
"We are very pleased to welcome Ms. DeBuono to Cadence's board of directors," stated Cam Garner, Chairman of Cadence. "Laureen has a wealth of experience in senior leadership positions with several private and public life sciences, medical technology and consumer products companies. We believe that her extensive background in developing and executing complex corporate and financial strategies will make her an important addition to our board, as we continue to explore opportunities to add new products to our portfolio for use within the hospital setting."
Ms. DeBuono has been a partner of FLG Partners, LLC, a leading CFO consulting services firm, since October 2011. Prior to joining FLG Partners, Ms. DeBuono served as President, CEO and member of the board of directors of Coapt Systems, Inc., and as Chief Financial Officer of Thermage, Inc. Previously, Ms. DeBuono served as consulting chief financial officer, executive vice president, chief operations officer and general counsel of several medical technology, consumer products, and technology companies. Ms. DeBuono is currently a member of the board of directors of two privately-held companies, Cradle Holdings, Inc., and VenX LLC. She previously served as a member of the board of directors and audit committee chair of two public companies, VISX, Inc. and InVivo Medical Diagnostics, Inc., and as a member of the board of two privately-held companies, Coapt Systems, Inc., and Alpha Orthopaedics, Inc. Ms. DeBuono is also a co-founder and co-chair of the MAIA Foundation, Inc., a non-profit 501(c)(3) corporation. Ms. DeBuono received a B.A. from Duke University, an M.A. from Stanford University and a J.D. from the New York University School of Law, and is a member of the State Bar of California.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the Investors page of www.cadencepharm.com under "Events & Presentations" by selecting "Corporate Overview."
CADENCE® and OFIRMEV® are registered trademarks of Cadence Pharmaceuticals, Inc.
William R. LaRue
SOURCE Cadence Pharmaceuticals, Inc.
More by this Source
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
Feb 28, 2014, 16:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.